Skip to main content

Advertisement

SpringerLink
Log in

Recurrent Salivary Gland Cancer

  • Head and Neck Cancer (T Day, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jeannon JP, Calman F, Gleeson M, et al. Management of advanced parotid cancer: a systematic review. Eur J Surg Oncol. 2009; 35: 908–915.

    Article  PubMed  Google Scholar 

  2. Surakanti SG, Agulnik M. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008; 35: 309–319.

    Article  PubMed  Google Scholar 

  3. Lee YYP, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumors. Eur J Radiol. 2008;66:419–36.

    Article  PubMed  CAS  Google Scholar 

  4. Shah GV. MR imaging of the salivary glands. Magn Reson Imaging Clin N Am. 2002;10:631–62.

    Article  PubMed  Google Scholar 

  5. Keyes JW, Harkness BA, Greven KM, et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99–102.

    PubMed  Google Scholar 

  6. www.nccn.org

  7. Cohen EG, Patel SG, Lin O, et al. Fine-needle aspiration biopsy of salivary gland lesions in a selected patient population. Arch Otolaryngol Head Neck Surg. 2004; 130: 773–778.

    Article  PubMed  Google Scholar 

  8. Kaszuba SM, Zafereo ME, Rosenthal DI, et al. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:546–50.

    Article  PubMed  Google Scholar 

  9. www.cancer.gov

  10. Skalova A, Leivo I, Von Boguslawsky K, Saksela E. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections. J Pathol. 1994;173:13–21.

    Article  PubMed  CAS  Google Scholar 

  11. Luukkaa H, Klemi P, Leivo I, et al. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol. 2006;45:669–75.

    Article  PubMed  Google Scholar 

  12. Nordgard S, Franzen G, Boysen M, Halvorsen TB. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope. 1997;107:531–6.

    Article  PubMed  CAS  Google Scholar 

  13. Miyabe S, Okabe M, Nagatsuka H, et al. Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases. J Oral Maxillofac Surg. 2009;67(7):1432–41.

    Article  PubMed  Google Scholar 

  14. Hoyek-Gebeily J, Nehme E, Aftimos G, et al. Prognostic significance of EGFR, p53 and E-cadherin in mucoepidermoid cancer of the salivary glands: a retrospective case series. J Med Liban. 2007;55:83–8.

    PubMed  Google Scholar 

  15. Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM. Expression and mutations of p53 in salivary gland tumours. J Oral Path Med. 1997;26:217–23.

    Article  CAS  Google Scholar 

  16. Kiyoshima T, Shima K, Kobayashi I, et al. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol. 2001;37:315–7.

    Article  PubMed  CAS  Google Scholar 

  17. Williams MD, Roberts DB, Lies MS, et al. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Can Res. 2010; 16: 2266–2274.

    Article  CAS  Google Scholar 

  18. Seethala RR, Dacic S, Cieply K, et al. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34:1106–21.

    Article  PubMed  Google Scholar 

  19. Okabe M, Miyabe S, Nagatsuka H, et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Can Res. 2006;12:3902–7.

    Article  CAS  Google Scholar 

  20. Okumura Y, Miyabe S, Nakayama T, et al. Impact of CRTC1/3-MAML2 fusions on histological classification and prognosis of mucoepidermoid carcinoma. Histopathology. 2011;59:90–7.

    Article  PubMed  Google Scholar 

  21. Ben-Izhak O, Akrish S, Gan S, Nagler RM. p27 and salivary cancer. Cancer Immunol Immunother. 2009;58:469–73.

    Article  PubMed  CAS  Google Scholar 

  22. Terhaard CHJ. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007; 69 Suppl: S52–S55. Excellent review of the role of radiotherapy for salivary cancer summarizing evidence concerning major issues.

  23. Alterio D, Jereczek-Fossa BA, Griseri M, et al. Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years experience at the European Institute of Oncology. Tumori. 2011;97:328–34.

    PubMed  Google Scholar 

  24. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009; 45: 574–578.

    Article  PubMed  CAS  Google Scholar 

  25. Mariano FV, da Silva SD, Chulan TC, et al. Clinicopathological factors are predictors of distant metastasis from major salivary gland carcinomas. Int J Oral Maxillofac Surg. 2011;40:504–9.

    Article  PubMed  CAS  Google Scholar 

  26. Westra WH, Kronz JD, Eisele DW. The impact of second opinion surgical pathology on the practice of head and neck surgery: a decade experience at a large referral hospital. Head Neck 2002; 24: 684–693.

    Article  PubMed  Google Scholar 

  27. Kobayashi K, Nakao K, Yoshida M, et al. Recurrent cancer of the parotid gland: how well does surgery work for locoregional failure? ORL J Otorhinolaryngol Relat Spec. 2009;71:239–43.

    Article  PubMed  Google Scholar 

  28. Pederson AW, Haraf DJ, Blair EA, et al. Chemoreirradiation for recurrent salivary malignancies. Radiother Oncol. 2010; 95: 308–311. Paper provides evidence of the relative safety of reirradiation protocols in recurrent salivary cancer.

    Article  PubMed  CAS  Google Scholar 

  29. Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011; 12: 815–824.

    Article  PubMed  CAS  Google Scholar 

  30. Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 905–911.

  31. Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer. Cancer. 2010;116:362–8.

    Article  PubMed  CAS  Google Scholar 

  32. Debaere D, Vander Poorten V, Nuyts S, et al. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT. 2011;7:1–6.

    PubMed  CAS  Google Scholar 

  33. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas: a phase 2 study. Oral Oncol. 2003;39:724–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Medical University of South Carolina, Charleston, USA

    M. Boyd Gillespie MD, MSc & W. Greer Albergotti BS

  2. University of California, San Francisco, USA

    David W. Eisele MD

  3. Department of Otolaryngology, Head and Neck Surgery, 135 Rutledge Avenue MSC 550, Charleston, SC, 29425-5500, USA

    M. Boyd Gillespie MD, MSc

Authors
  1. M. Boyd Gillespie MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Greer Albergotti BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David W. Eisele MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Boyd Gillespie MD, MSc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gillespie, M.B., Albergotti, W.G. & Eisele, D.W. Recurrent Salivary Gland Cancer. Curr. Treat. Options in Oncol. 13, 58–70 (2012). https://doi.org/10.1007/s11864-011-0174-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0174-0

Keywords

Search

Navigation